# Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

> **NCT04089527** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 24 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** CC-95775

## Key facts

- **NCT ID:** NCT04089527
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-24
- **Primary completion:** 2021-10-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089527, "Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04089527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*